Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences has established a Scientific Advisory Board (SAB) composed of leading experts in psychiatry and neuroscience to guide the clinical development of roluperidone, an investigational drug targeting negative symptoms of schizophrenia, and to advise on future pipeline programs. The SAB formation fulfills a prior PIPE financing commi…